#natalizumabe

[krishgen]

GENLISA™ KITa - Kyushu Lung Cancer Antigen 1 (CXorf61) Detection Kit

The GENLISA™ KITa is an advanced enzyme immunoassay designed for the precise quantification of Kyushu Lung Cancer Antigen 1 (CXorf61) in various biological fluids. This kit can be used to measure CXorf61 levels in serum, plasma, tissue homogenates, and other related samples. CXorf61, a biomarker linked to lung cancer, plays a key role in early diagnosis and monitoring of the disease. The GENLISA™ KITa offers a reliable, sensitive, and efficient solution for research and clinical applications, facilitating enhanced understanding and management of lung cancer progression and patient prognosis.

[portalg37]

Anvisa alerta sobre lotes falsificados de dois medicamentos

Tysabri é indicado para esclerose e Ozempic, para diabetes tipo 2 A Agência Nacional de Vigilância Sanitária (Anvisa) publicou, nesta sexta-feira (3), em seu site, um alerta aos profissionais de saúde e à população sobre lotes falsificados de dois medicamentos: Tysabri® (que contém a substância ativa natalizumabe), indicado para tratamento de formas mais ativas de esclerose múltipla, e…

[ocombatenterondonia]

Anvisa alerta sobre lotes falsificados de dois medicamentos

A Agência Nacional de Vigilância Sanitária (Anvisa) publicou, nesta sexta-feira (3), em seu site, um alerta aos profissionais de saúde e à população sobre lotes falsificados de dois medicamentos: Tysabri® (que contém a substância ativa natalizumabe), indicado para tratamento de formas mais ativas de esclerose múltipla, e Ozempic® (o princípio ativo semaglutida), para tratar, em conjunto com dieta…

[puravibenamastes-blog]

Anvisa emite alerta sobre medicamentos Tysabri e Ozempic falsificados; veja os lotes

A Anvisa (Agência Nacional de Vigilância Sanitária) emitiu um alerta nesta sexta (3) a respeito da circulação de lotes falsificados do Tysabri (natalizumabe), para tratamento de esclerose múltipla, e Ozempic (semaglutida), indicado a adultos com diabetes tipo 2 -este último noticiado pela Folha em 25 de outubro. Leia mais (11/03/2023 – 16h33) Artigo Folha de S.Paulo – Equilíbrio e Saúde –…

[healthkenya7]

PROMISING THERAPIES AND POTENTIAL CURES FOR MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, specifically the brain and spinal cord. It is characterized by the immune system attacking the protective covering of nerve fibers, known as myelin, leading to inflammation, demyelination (loss of myelin), and a range of neurological symptoms. While there is currently no known cure for MS, there are several promising therapies and potential treatments that aim to manage symptoms, slow disease progression, and improve the quality of life for individuals with MS.

Disease-Modifying Therapies (DMTs): These treatments are designed to modify the course of the disease by reducing the frequency and severity of relapses, slowing down disability progression, and delaying the accumulation of new lesions in the brain and spinal cord. There are several classes of DMTs, including interferons, glatiramer acetate, oral immunomodulators, and monoclonal antibodies. Some examples of DMTs include:

Interferons: These are proteins that help regulate the immune system. They can reduce inflammation and the frequency of relapses. Examples include interferon beta-1a and interferon beta-1b.

Glatiramer Acetate: This is a synthetic protein that mimics myelin basic protein, helping to divert the immune system's attack away from the actual myelin.

Oral Immunomodulators: Drugs like fingolimod, siponimod, and teriflunomide modulate immune responses and reduce inflammation. They are taken orally.

Monoclonal Antibodies: Medications like ocrelizumab, alemtuzumab, and natalizumab target specific immune cells or molecules involved in the disease process.

Stem Cell Therapy: Stem cell transplantation involves replacing the immune system with healthy stem cells derived from the patient's own bone marrow or from a donor. This treatment aims to "reset" the immune system and halt the autoimmune attack on myelin. Autologous hematopoietic stem cell transplantation (aHSCT) has shown promising results in clinical trials for aggressive forms of relapsing-remitting MS.

B-cell Depletion: B cells are a type of immune cell that plays a role in the autoimmune response in MS. Monoclonal antibodies targeting CD20-positive B cells, such as ocrelizumab and rituximab, have been shown to reduce relapse rates and disability progression.

Neuroprotection and Remyelination: Some therapies focus on protecting nerve cells and promoting remyelination to repair damaged myelin. These approaches are still in experimental stages but show potential. Drugs like clemastine and opicinumab are being investigated for their ability to enhance remyelination.

Vitamin D Supplementation: There is evidence suggesting that vitamin D deficiency might play a role in MS development and progression. Some studies have shown that maintaining adequate levels of vitamin D through supplementation could have a positive impact on disease activity.

Anti-Inflammatory and Immunosuppressive Therapies: These treatments aim to control the immune response and reduce inflammation. Drugs like corticosteroids are often used to manage acute relapses and reduce inflammation in the central nervous system.

Myelin Repair Therapies: Researchers are exploring strategies to stimulate the repair and regrowth of damaged myelin. This includes promoting the differentiation of oligodendrocyte precursor cells into mature myelin-producing cells.

Personalized Medicine: With advancements in genetics and understanding of individual disease characteristics, personalized treatment plans are becoming more common. Tailoring therapies to the patient's specific disease profile could lead to better outcomes.

Mr. Jayesh Saini notes that, “The effectiveness of these therapies can vary from person to person, and treatment decisions should be made in consultation with a qualified healthcare provider. While significant progress has been made in the field of MS treatment, ongoing research is essential to continue improving therapies and potentially finding a cure in the future.”

#jayeshsaini #healthcare #LifeCareHospitals #Kenya #NHIF #NPS #TSC

[healthwisekenya]

PROMISING THERAPIES AND POTENTIAL CURES FOR MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system,

specifically the brain and spinal cord. It is characterized by the immune system attacking the

protective covering of nerve fibers, known as myelin, leading to inflammation, demyelination

(loss of myelin), and a range of neurological symptoms. While there is currently no known cure

for MS, there are several promising therapies and potential treatments that aim to manage

symptoms, slow disease progression, and improve the quality of life for individuals with MS.

Disease-Modifying Therapies (DMTs): These treatments are designed to modify the course of

the disease by reducing the frequency and severity of relapses, slowing down disability

progression, and delaying the accumulation of new lesions in the brain and spinal cord. There are

several classes of DMTs, including interferons, glatiramer acetate, oral immunomodulators, and

monoclonal antibodies. Some examples of DMTs include:

• Interferons: These are proteins that help regulate the immune system. They can reduce

inflammation and the frequency of relapses. Examples include interferon beta-1a and

interferon beta-1b.

• Glatiramer Acetate: This is a synthetic protein that mimics myelin basic protein, helping

to divert the immune system's attack away from the actual myelin.

• Oral Immunomodulators: Drugs like fingolimod, siponimod, and teriflunomide modulate

immune responses and reduce inflammation. They are taken orally.

• Monoclonal Antibodies: Medications like ocrelizumab, alemtuzumab, and natalizumab

target specific immune cells or molecules involved in the disease process.

Stem Cell Therapy: Stem cell transplantation involves replacing the immune system with healthy

stem cells derived from the patient's own bone marrow or from a donor. This treatment aims to

"reset" the immune system and halt the autoimmune attack on myelin. Autologous

hematopoietic stem cell transplantation (aHSCT) has shown promising results in clinical trials for

aggressive forms of relapsing-remitting MS.

B-cell Depletion: B cells are a type of immune cell that plays a role in the autoimmune response

in MS. Monoclonal antibodies targeting CD20-positive B cells, such as ocrelizumab and rituximab,

have been shown to reduce relapse rates and disability progression.

Neuroprotection and Remyelination: Some therapies focus on protecting nerve cells and

promoting remyelination to repair damaged myelin. These approaches are still in experimental

stages but show potential. Drugs like clemastine and opicinumab are being investigated for their

ability to enhance remyelination.

Vitamin D Supplementation: There is evidence suggesting that vitamin D deficiency might play a

role in MS development and progression. Some studies have shown that maintaining adequate

levels of vitamin D through supplementation could have a positive impact on disease activity.

Anti-Inflammatory and Immunosuppressive Therapies: These treatments aim to control the

immune response and reduce inflammation. Drugs like corticosteroids are often used to manage

acute relapses and reduce inflammation in the central nervous system.

Myelin Repair Therapies: Researchers are exploring strategies to stimulate the repair and

regrowth of damaged myelin. This includes promoting the differentiation of oligodendrocyte

precursor cells into mature myelin-producing cells.

Personalized Medicine: With advancements in genetics and understanding of individual disease

characteristics, personalized treatment plans are becoming more common. Tailoring therapies

to the patient's specific disease profile could lead to better outcomes.

Mr. Jayesh Saini notesthat, “The effectiveness of these therapies can vary from person to person,

and treatment decisions should be made in consultation with a qualified healthcare provider.

While significant progress has been made in the field of MS treatment, ongoing research is

essential to continue improving therapies and potentially finding a cure in the future.”

[mariebenz]

Genetic Test Can Predict Predisposition to Drug-Induced Brain Infection PML

MedicalResearch.com Interview with:

Dr. Hatchwell Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU) Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom MedicalResearch.com: What is the background for this study? Response: Progressive Multifocal Leukoencephalopathy (PML) is a devastating condition that is associated with a number of clinical situations, including treatment with a variety of drugs. Of these, the best known is natalizumab (Tysabri), which is a very successful drug in the treatment of MS (multiple sclerosis). Only a small proportion of patients treated with natalizumab develop PML and this has always been a mystery. The study was based on a hypothesis that some individuals have an underlying susceptibility to developing PML, based on the presence of variants in genes that are important in the immune system. The study identified several of these variants. MedicalResearch.com:   Where is the polyomavirus 2 found?  Response: The polyoma 2 virus (aka JCV) has an estimated worldwide prevalence of 40–70%. More recent studies in Asian populations showed even higher rates, ranging from 70- 80%. In the body, the virus is found particularly in the kidneys in a dormant state but in PML, it is found at high levels in the brain. MedicalResearch.com: What are the main findings? Response:  The study describes four variants that may account for 11% of drug-induced PML. Individuals with one or more of these variants are predicted to be at significantly higher risk of Progressive Multifocal Leukoencephalopathy compared to those who test negative. These variants are in genes with known roles in not only the immune system but also viral defense. MedicalResearch.com: What should readers take away from your report? Response: For the first time, a specific test is available that predicts an individual’s risk of Progressive Multifocal Leukoencephalopathy. The test should be implemented clinically to inform physicians and their patients of their individual risk for PML. Those who test positive are advised to avoid drugs with especially high risks of PML (in particular, Tysabri). MedicalResearch.com: What recommendations do you have for future research as a results of this study? Response: The insights gleaned from this study pave the way for future studies to expand the number of genes/variants that are implicated in Progressive Multifocal Leukoencephalopathy risk. Further, some of the insights may suggest interventions that will help treat PML. We view our study as a demonstration of the power of precision medicine in relation to drug adverse events. Disclosures: I am Chief Scientific Officer and co-founder of Population Bio.  Citation: Progressive Multifocal Leukoencephalopathy Genetic Risk Variants for Pharmacovigilance Immunosuppressant Therapies Link to article: https://www.frontiersin.org/articles/10.3389/fneur.2022.1016377/full doi: 10.3389/fneur.2022.1016377 The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website. Read the full article

[alsapem]

3 anos do diagnóstico que me tirou do eixo que eu achava que tinha controle, tudo saiu do lugar e foi um tempo pra acontecer um reencontro com minha essência e aceitar a nova condição, o balancete desse último ano foi positivo, 1 ano sem surtos ( nome dado as crises de Esclerose Múltipla, não são surtos de "loucura"...rs), sem internações...Viva!!! Metade desse êxito provém dos bons especialistas que me acompanham, da medicação que tenho acesso, entretanto a outra metade é do meu esforço diário, terapia em dia, fisioterapia em dia, relações selecionadas, óleos essenciais, momentos só meus e massagens da Pretinha...rs E, assim entendi 'a pegada', que metade do sucesso a responsável SOU EU!!! Ontem fiz o passeio que prometi fazer todo dia 16/07... Sou boa em cumprir promessas, principalmente as que faço pra mim. . #multiplesclerosis #forçag35 #tysabri #natalizumabe #Repost @lilianandrereis ... https://www.instagram.com/p/CRaSeh4gX3c/?utm_medium=tumblr

[abstractvisual]

⭐️⭐️⭐️🔅🔅

[ihollinsworth-blog]

Do you look at yourself in the mirror regularly? I tend not to. 📸 Do you like taking selfies and splashing them over the soc-med? 🙋🏼‍♂️💁🏼‍♂️🙆🏼‍♂️🙅🏼‍♂��🤷🏼‍♂️🤦🏼‍♂️🙍🏼‍♂️🙎🏼‍♂️🧘🏼‍♂️⛷️🤸🤺🧙🐑🍧🍱🍹👫💏 I dont. I don't like being in pictures. This picture (all pictures actually) make me feel uncomfortable. But I took it to #BeUncomfortable And I'm on unlimited data 😜 I'm Feeling a bit tired today. I've been Teaching 6 days a week, plus all the other stuff, for a long time. Most of the time I am (have been) fine. Not a problem. But I'm noticing it a bit more; being tired. It is also week 3 in the Treatment cycle -next Wednesday is #tysabri time. So i will feel a bit more lively then 👊🏃 Now this isn't to have a moan or complain like 'oh my life is so bad' or 'feel sorry for me' to hell with that self-pitiest Pish! What I want is to train more. 💪🥋 I could run more because I don't need anyone for that. But #martialarts training I do (it's the way I am #lazybastard) There's isn't anyone close-by that is any good. That could push me. That could motivate me to try hard. . . . . . #autoimmunedisorder #autoimmunedisease #multiplesclerosis #ms #taekwondo #itf #taekwondotraining #itfinstructor #martialartsinstructor #kickmyass #tysabri #natalizumab #motivational #motivateme #autoimmunication #mswarrior #ihaterunning #redrunningshoes #redrunningshoesdiary #instagram #facebook #twitter #tumblr #hashtag (at Alton, Hampshire) https://www.instagram.com/p/B2HczuQgwX8/?igshid=14z16o6d9sd6q

[neurosciencenews]

AI used to detect brain’s response to multiple sclerosis treatment

Combining artificial intelligence technology with MRI brain scans, researchers are able to detect the brain’s response to Natalizumab treatment for those with relapsing-remitting multiple sclerosis.

[teachingrounds]

Drugs that can be used to treat Multiple Sclerosis (MS), Part 2 of 3: Oral Disease-Modifying Agents (DMAs)

Dimethyl fumarate (Tecfidera)--DMF and its active metabolite, monomethyl fumarate (MMF), activate a cellular response pathway that responds to oxidative stress. Comes in 120 mg and 240 mg delayed-release capsules. Maintenance dose is 240 mg BID. Taken with food and/or aspirin to reduce flushing. May also cause GI upset and leukopenia/infection. There has been one case of fatal progressive multifocal leukoencephalopathy (PML) secondary to prolonged severe lymphopenia in Canada.

Fingolimod (Gilenya)--Sphingosine 1-Phosphate (S1P) Receptor Modulator that blocks WBCs' ability to leave lymph nodes, thereby decreased CNS inflammation. Dosage is 0.5 mg daily. May increase AST/ALT, especially in patients with hepatic impairment. Contraindicated in patients with most cardiac pathologies and/or CVA/TIA because it can cause HTN, AV block, bradycardia, and/or QT prolongation. There has been one reported case of (non-fatal) PML following the administration of Gilenya to a patient who had not previously received Tysabri (natalizumab), an MS drug associated with a higher risk of PML. Follow CBC, LFTs, EKG, ophthalmologic exam, VZV antibodies, and PFTs as indicated.

Teriflunomide (Aubagio)--A pyrimidine synthesis inhibitor that has antiproliferative and anti-inflammatory effects and may reduce the number of activated lymphocytes in the CNS. It is given 7 mg or 14 mg PO daily. It has the potential for significant hepatotoxicity, so monitor LFTs. It is teratogenic. May cause alopecia.

[healthwisekenya]

PROMISING THERAPIES AND POTENTIAL CURES FOR MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system,

specifically the brain and spinal cord. It is characterized by the immune system attacking the

protective covering of nerve fibers, known as myelin, leading to inflammation, demyelination

(loss of myelin), and a range of neurological symptoms. While there is currently no known cure

for MS, there are several promising therapies and potential treatments that aim to manage

symptoms, slow disease progression, and improve the quality of life for individuals with MS.

Disease-Modifying Therapies (DMTs): These treatments are designed to modify the course of

the disease by reducing the frequency and severity of relapses, slowing down disability

progression, and delaying the accumulation of new lesions in the brain and spinal cord. There are

several classes of DMTs, including interferons, glatiramer acetate, oral immunomodulators, and

monoclonal antibodies. Some examples of DMTs include:

• Interferons: These are proteins that help regulate the immune system. They can reduce

inflammation and the frequency of relapses. Examples include interferon beta-1a and

interferon beta-1b.

• Glatiramer Acetate: This is a synthetic protein that mimics myelin basic protein, helping

to divert the immune system's attack away from the actual myelin.

• Oral Immunomodulators: Drugs like fingolimod, siponimod, and teriflunomide modulate

immune responses and reduce inflammation. They are taken orally.

• Monoclonal Antibodies: Medications like ocrelizumab, alemtuzumab, and natalizumab

target specific immune cells or molecules involved in the disease process.

Stem Cell Therapy: Stem cell transplantation involves replacing the immune system with healthy

stem cells derived from the patient's own bone marrow or from a donor. This treatment aims to

"reset" the immune system and halt the autoimmune attack on myelin. Autologous

hematopoietic stem cell transplantation (aHSCT) has shown promising results in clinical trials for

aggressive forms of relapsing-remitting MS.

B-cell Depletion: B cells are a type of immune cell that plays a role in the autoimmune response

in MS. Monoclonal antibodies targeting CD20-positive B cells, such as ocrelizumab and rituximab,

have been shown to reduce relapse rates and disability progression.

Neuroprotection and Remyelination: Some therapies focus on protecting nerve cells and

promoting remyelination to repair damaged myelin. These approaches are still in experimental

stages but show potential. Drugs like clemastine and opicinumab are being investigated for their

ability to enhance remyelination.

Vitamin D Supplementation: There is evidence suggesting that vitamin D deficiency might play a

role in MS development and progression. Some studies have shown that maintaining adequate

levels of vitamin D through supplementation could have a positive impact on disease activityAnti-Inflammatory and Immunosuppressive Therapies: These treatments aim to control the

immune response and reduce inflammation. Drugs like corticosteroids are often used to manage

acute relapses and reduce inflammation in the central nervous system.

Myelin Repair Therapies: Researchers are exploring strategies to stimulate the repair and

regrowth of damaged myelin. This includes promoting the differentiation of oligodendrocyte

precursor cells into mature myelin-producing cells.

Personalized Medicine: With advancements in genetics and understanding of individual disease

characteristics, personalized treatment plans are becoming more common. Tailoring therapies

to the patient's specific disease profile could lead to better outcomes.

Mr. Jayesh Saini notesthat, “The effectiveness of these therapies can vary from person to person,

and treatment decisions should be made in consultation with a qualified healthcare provider.

While significant progress has been made in the field of MS treatment, ongoing research is

essential to continue improving therapies and potentially finding a cure in the future.”